Drugmakers renew interest in antibiotic development

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

Five things for pharma marketers to know: Friday, May 27, 2016

Five things for pharma marketers to know: Friday, May 27, 2016

Baby powder lawsuit impacts J&J's reputation; new bacterial infection raises concern about treatment options; Valeant reportedly rejected offer from Takeda

AstraZeneca pulls Take it From a Fish campaign

AstraZeneca pulls Take it From a Fish campaign

The unbranded campaign won the top prize at the 2015 Lions Health festival in Cannes.

Five things for pharma marketers to know: Thursday, May 26, 2016

Five things for pharma marketers to know: Thursday, May 26, 2016

BIO report finds success rate in Phase-I is 10%; Dunsire departs Forum after failed trials; the FDA issues two warning letters

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Infographic: Merck's Keytruda versus Bristol-Myers Squibb's Opdivo

Here, see side-by-side comparisons of the drugs spending on advertising, approval dates, and 2015 sales figures.

The commercial carousel continues to spin: Gilead's head of commercial departs

The commercial carousel continues to spin: Gilead's head of commercial departs

Gilead announced that its head of commercial operations left the company.

Conflicting polls highlight uncertainty about the public's opinion of pharma

Conflicting polls highlight uncertainty about the public's opinion of pharma

Two recent polls paint a complicated picture of the public's opinion of the pharma industry.

Five things for pharma marketers to know: Wednesday, May 25, 2016

Five things for pharma marketers to know: Wednesday, May 25, 2016

Antidepressants are often used to treat conditions other than depression; the FDA delays decision on Duchenne drug; Lilly and Pfizer develop new painkiller

What do physicians think about biosimilars?

What do physicians think about biosimilars?

A SERMO poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Five things for pharma marketers to know: Tuesday, May 24, 2016

Five things for pharma marketers to know: Tuesday, May 24, 2016

The FDA accepts Samsung's biosimilar for review; Sanofi retools executive committee; Entresto may get a boost from updated care guidelines

Practice Fusion founder launches heart-monitoring wearable

Practice Fusion founder launches heart-monitoring wearable

The new company, iBeat, plans to market a wearable device that can detect the symptoms of cardiac arrest and heart attacks.

Pfizer's smoking-cessation app came from internal competition

Pfizer's smoking-cessation app came from internal competition

Pfizer brand teams competed in a shark-tank style challenge, with the winning teams receiving funding for their ideas.

J&J taps Sneed as communications chief

J&J taps Sneed as communications chief

Johnson & Johnson has appointed Michael Sneed, its worldwide VP of global corporate affairs, to the additional role of chief communications officer.

4 trends with the potential to change behavior in the patient journey

4 trends with the potential to change behavior in the patient journey

It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.

Five things for pharma marketers to know: Monday, May 23, 2016

Five things for pharma marketers to know: Monday, May 23, 2016

E.U. lifts warning on Pfizer's Chantix; Obama's Medicare Part B proposal panned by lawmakers; France to propose stricter rules for clinical trials

Top 25 infectious disease products in 2015

Top 25 infectious disease products in 2015

To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.

Agency Spotlight


OPINION

Email Newsletters